Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
5 "Sei-Chul Yoon"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung Cancer
Dong-Soo Lee, Yeon-Sil Kim, Jin-Hyoung Kang, Sang-Nam Lee, Young-Kyoun Kim, Myung-Im Ahn, Dae-Hee Han, Ie-Ryung Yoo, Young-Pil Wang, Jae-Gil Park, Sei-Chul Yoon, Hong-Seok Jang, Byung-Oak Choi
Cancer Res Treat. 2011;43(1):32-41.   Published online March 31, 2011
DOI: https://doi.org/10.4143/crt.2011.43.1.32
AbstractAbstract PDFPubReaderePub
PURPOSE
To evaluate treatment outcomes and prognostic factors in non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiation.
MATERIALS AND METHODS
From January 2005 to June 2009, 51 patients were treated with concurrent chemoradiation for 3 different aims: locally advanced stage III, locally recurrent disease, and postoperative gross residual NSCLC. Median age was 63 years. Distribution of stages by the 6th edition of American Joint Committee on Cancer (AJCC) was as follows: IIIA (37.3%), IIIB (56.9%). Chemotherapy was administered every week concurrently with radiation using one of the following regimens: paclitaxel (60 mg/m2), docetaxel+cisplatin (20 mg/m2+20 mg/m2), cisplatin (30 mg/m2). Total radiation dose was 16-66.4 Gy (median, 59.4 Gy).
RESULTS
Median follow-up duration was 40.8 months. The overall response rate was 84.3% with 23 complete responses. The median survival duration for the overall patient group was 17.6 months. The 3-year survival rate was 17.8%. A total of 21 patients had recurrent disease at the following sites: loco-regional sites (23.6%), distant organs (27.5%). In the multivariate analysis of the overall patient group, a clinical tumor response (p=0.002) was the only significant prognostic factor for overall survival (OS). In the multivariate analysis of the definitive chemoradiation arm, the use of consolidation chemotherapy (p=0.022), biologically equivalent dose (BED)10 (p=0.007), and a clinical tumor response (p=0.030) were the significant prognostic factors for OS.The median survival duration of the locally recurrent group and the postoperative gross residual group were 26.4 and 23.9 months, respectively.
CONCLUSION
Our study demonstrated that clinical tumor response was significantly associated with OS in the overall patient group. Further investigations regarding the optimal radiation dose in the definitive chemoradiation and the optimal treatment scheme in locally recurrent NSCLC would be required.

Citations

Citations to this article as recorded by  
  • A scoping review on population-centered indicators for cancer care continuum
    Vasuki Rajaguru, Jieun Jang, Jeoung A. Kwon, Jae Hyun Kim, Jaeyong Shin, Mison Chun
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases
    Lipin Liu, Nan Bi, Zhe Ji, Junling Li, Jingbo Wang, Xiaozhen Wang, Zhouguang Hui, Jima Lv, Jun Liang, Zongmei Zhou, Yan Wang, Weibo Yin, Luhua Wang
    BMC Cancer.2015;[Epub]     CrossRef
  • Treatment-related Lymphopenia in Patients With Stage III Non-Small-Cell Lung Cancer
    Jian L. Campian, Xiaobu Ye, Malcolm Brock, Stuart A. Grossman
    Cancer Investigation.2013; 31(3): 183.     CrossRef
  • Does Pneumonectomy Have a Role in the Treatment of Stage IIIA Non-Small Cell Lung Cancer?
    Asad A. Shah, Mathias Worni, Christopher R. Kelsey, Mark W. Onaitis, Thomas A. D'Amico, Mark F. Berry
    The Annals of Thoracic Surgery.2013; 95(5): 1700.     CrossRef
  • Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy
    Gangjun Du, Yingming Yang, Yaping Zhang, Ting Sun, Weijie Liu, Yingying Wang, Jiahuan Li, Houyun Zhang
    Cancer Chemotherapy and Pharmacology.2013; 71(4): 893.     CrossRef
  • 11,222 View
  • 67 Download
  • 5 Crossref
Close layer
Radiation Therapy Combined with (or without) Cisplatin-based Chemotherapy for Patients with Nasopharyngeal Cancer: 15-years Experience of a Single Institution in Korea
Yeon-Sil Kim, Bum-Soo Kim, So-Lyoung Jung, Yeon-Soo Lee, Min-Sik Kim, Dong-Il Sun, Eun-Jung Yoo, Seong-Kwon Mun, Sei-Chul Yoon, Su-Mi Chung, Hoon-Kyo Kim, Seung-Ho Jo, Jin-Hyoung Kang
Cancer Res Treat. 2008;40(4):155-163.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.155
AbstractAbstract PDFPubReaderePub
Purpose

This retrospective study was carried out to evaluate the efficacy and toxicity of radiation therapy (RT) with/without cisplatin-based chemotherapy in nasopharyngeal cancer (NPC).

Materials and Methods

One hundred forty six patients with NPC received curative RT and/or cisplatin-based chemotherapy. Thirty-nine patients were treated with induction chemotherapy (IC), including cisplatin and 5-fluorouracil followed by RT. Another 63 patients were treated with concurrent chemoradiotherapy (CCRT) using cisplatin, and 22 patients were treated with IC followed by CCRT. The remaining 22 patients were treated with RT alone.

Results

One hundred four (80.0%) patients achieved complete response (CR), and 23 (17.7%) patients achieved partial response (PR). The patterns of failure were: locoregional recurrences in 21.2% and distant metastases in 17.1%. Five-year overall survival (OS) and progression free survival (PFS) were 50.7% and 45.0%, respectively. Multivariate Cox stepwise regression analysis revealed CR to chemoradiotherapy to be a powerful prognostic factor for OS. CR to chemoradiotherapy and completion of radiation according to the time schedule were favorable prognostic factors for PFS. A comparison of each treatment group (IC → RT vs. CCRT vs. IC → CCRT vs. RT alone) revealed no significant differences in the OS or PFS. However, subgroup analysis showed significant differences in both OS and DFS in favor of the combined chemoradiotherapy group compared with RT alone, for stage IV and T3-4 tumors. Grade 3-4 toxicities were more common in the combined chemoradiotherapy arm, particularly in the CCRT group.

Conclusions

This study was limited in that it was a retrospective study, much time was required to collect patients, and there were imbalances in the number of patients in each treatment group. Combined chemoradiotherapy remarkably prolonged the OS and PFS in subgroup patients with stage IV or T3-4 NPC.

Citations

Citations to this article as recorded by  
  • Effects of SENP1-induced deSUMOylation of STAT1 on proliferation and invasion in nasopharyngeal carcinoma
    Jun Zhang, Guo-lin Tan, Ming Jiang, Tian-sheng Wang, Guo-hui Liu, Shan-shan Xiong, Xiang Qing
    Cellular Signalling.2023; 101: 110530.     CrossRef
  • SEPT9, H4C6, and RASSF1A methylation in nasopharyngeal swabs: A reflection of potential minimally invasive biomarkers for early screening of nasopharyngeal cancer
    Tai Qian, Zhiwei Zhou, Qiongxia Zhang, Yu-Light Liou, Honghao Zhou
    Medicine.2023; 102(50): e36583.     CrossRef
  • MicroRNA-145-5p modulates Krüppel-like factor 5 and inhibits cell proliferation, migration, and invasion in nasopharyngeal carcinoma
    Chien-Han Yuan, Wei-Chi Hsu, A.-Mei Huang, Ben-Chih Yuan, I.-Hung Chen, Chia-An Hsu, Rong-Feng Chen, Yih-Min Chu, Hui-Hui Lin, Hung-Lung Ke
    BMC Molecular and Cell Biology.2022;[Epub]     CrossRef
  • Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma
    Fen Xue, Dan Ou, Xiaomin Ou, Xin Zhou, Chaosu Hu, Xiayun He
    Oral Oncology.2022; 134: 106139.     CrossRef
  • Transcription Factor STAT1 Promotes the Proliferation, Migration and Invasion of Nasopharyngeal Carcinoma Cells by Upregulating LINC01160
    Jingang Ai, Guolin Tan, Tiansheng Wang, Wei Li, Ru Gao, Yexun Song, Shanshan Xiong, Xiang Qing
    Future Oncology.2021; 17(1): 57.     CrossRef
  • RETRACTED ARTICLE: Inhibition of PAD4 enhances radiosensitivity and inhibits aggressive phenotypes of nasopharyngeal carcinoma cells
    Hao Chen, Min Luo, Xiangping Wang, Ting Liang, Chaoyuan Huang, Changjie Huang, Lining Wei
    Cellular & Molecular Biology Letters.2021;[Epub]     CrossRef
  • DNA methylation biomarkers for nasopharyngeal carcinoma
    Baoai Han, Xiuping Yang, Po Zhang, Ya Zhang, Yaqin Tu, Zuhong He, Yongqin Li, Jie Yuan, Yaodong Dong, Davood K. Hosseini, Tao Zhou, Haiying Sun, Edwin Wang
    PLOS ONE.2020; 15(4): e0230524.     CrossRef
  • Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Nasopharyngeal Carcinoma Patients after Comprehensive Therapy
    Yueli Tian, Khamis Hassan Bakari, Shanshan Liao, Xiaotian Xia, Xun Sun, Chunxia Qin, Yongxue Zhang, Xiaoli Lan
    Contrast Media & Molecular Imaging.2018; 2018: 1.     CrossRef
  • MiRNA-34a reversed TGF-β-induced epithelial-mesenchymal transition via suppression of SMAD4 in NPC cells
    Guanhong Huang, Ming-yu Du, Hongming Zhu, Nan Zhang, Zhi-Wei Lu, Lu-Xi Qian, Wenjun Zhang, Xiaokang Tian, Xia He, Li Yin
    Biomedicine & Pharmacotherapy.2018; 106: 217.     CrossRef
  • Long non-coding RNA n326322 promotes the proliferation and invasion in nasopharyngeal carcinoma
    Mingyu Du, Teng Huang, Jing Wu, Jia-Jia Gu, Nan Zhang, Kai Ding, Lu-Xi Qian, Zhi-Wei Lu, Wen-Jun Zhang, Xiao-Kang Tian, Xia He, Li Yin
    Oncotarget.2018; 9(2): 1843.     CrossRef
  • GALNT7, a target of miR-494, participates in the oncogenesis of nasopharyngeal carcinoma
    Guo-Hui Nie, Liang Luo, Hong-Fang Duan, Xiao-Qing Li, Mei-Jun Yin, Zhao Li, Wei Zhang
    Tumor Biology.2016; 37(4): 4559.     CrossRef
  • The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis
    Jin Ho Song, Hong-Gyun Wu, Bhum Suk Keam, Jeong Hun Hah, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Hyo Jung Park, Chang Geol Lee, Ki Chang Keum, Jihye Cha, Kwan Ho Cho, Sung Ho Moon, Ji-Yoon Kim, Woong-Ki Chung, Young Taek Oh, Won Taek Kim, Moon-June Ch
    Cancer Research and Treatment.2016; 48(3): 917.     CrossRef
  • MicroRNA-15a Inhibits Proliferation and Induces Apoptosis in CNE1 Nasopharyngeal Carcinoma Cells
    Kang Zhu, Ying He, Cui Xia, Jing Yan, Jin Hou, Demin Kong, Yeye Yang, Guoxi Zheng
    Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.2016; 24(3): 145.     CrossRef
  • Functional elucidation of miR-494 in the tumorigenesis of nasopharyngeal carcinoma
    Hong-Fang Duan, Xiao-Qing Li, Hong-Yi Hu, Yu-Chi Li, Zhi Cai, Xue-Shuang Mei, Peng Yu, Li-Ping Nie, Wei Zhang, Zhen-Dong Yu, Guo-Hui Nie
    Tumor Biology.2015; 36(9): 6679.     CrossRef
  • Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy
    Seung Hwan Moon, Joon Young Choi, Hwan Joo Lee, Young-Ik Son, Chung-Hwan Baek, Yong Chan Ahn, Myung-Ju Ahn, Keunchil Park, Byung-Tae Kim
    Clinical and Experimental Otorhinolaryngology.2015; 8(2): 142.     CrossRef
  • MiR-145, a microRNA targeting ADAM17, inhibits the invasion and migration of nasopharyngeal carcinoma cells
    Jing Wu, Li Yin, Ning Jiang, Wen-jie Guo, Jia-jia Gu, Meng Chen, You-you Xia, Jian-zhong Wu, Dan Chen, Jian-feng Wu, De-jun Wang, Dan Zong, Nan Zhang, Kai Ding, Teng Huang, Xia He
    Experimental Cell Research.2015;[Epub]     CrossRef
  • miR‐539 induces cell cycle arrest in nasopharyngeal carcinoma by targeting cyclin‐dependent kinase 4
    Ling‐yan Lv, Yu‐zhi Wang, Qian Zhang, Hong‐rui Zang, Xing‐jie Wang
    Cell Biochemistry and Function.2015; 33(8): 534.     CrossRef
  • Chemotherapy of Head and Neck Cancer
    Chang Ki Yeo
    Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2014; 57(5): 291.     CrossRef
  • MicroRNA‐320a inhibits cell proliferation, migration and invasion by targeting BMI‐1 in nasopharyngeal carcinoma
    Xiaoming Qi, Jianqiang Li, Changbo Zhou, Chunlei Lv, Min Tian
    FEBS Letters.2014; 588(20): 3732.     CrossRef
  • IMRT with Simultaneous Integrated Boost and Concurrent Chemotherapy for Nasopharyngeal Cancer: Plan Evaluation and Treatment Outcome
    J. W. Kim, J. H. Cho, K. C. Keum, J. H. Kim, G. E. Kim, J. Y. Lee, S. K. Kim, C. G. Lee
    Japanese Journal of Clinical Oncology.2012; 42(12): 1152.     CrossRef
  • Does the prognosis of nasopharyngeal cancer differ among endemic and non-endemic regions?
    Senem Demirci, Serra Kamer, Gulsen Kara, Ozgur Yildirim, Mustafa Esassolak
    Acta Oto-Laryngologica.2011; 131(8): 852.     CrossRef
  • miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion
    Hongping Xia, Samuel S. Ng, Songshan Jiang, William K.C. Cheung, Johnny Sze, Xiu-Wu Bian, Hsiang-fu Kung, Marie C. Lin
    Biochemical and Biophysical Research Communications.2010; 391(1): 535.     CrossRef
  • 10,963 View
  • 67 Download
  • 22 Crossref
Close layer
The Effect of Simulation on Recurrence after Breast-Conserving Surgery and Radiotherapy: Preliminary Results
Ji-Yoon Kim, Yeon-Sil Kim, Mi-Ryung Ryu, Sung-Whan Kim, Chul-Seung Kay, Sei-Chul Yoon, Woo-Chan Park, Byung-Joo Song, Se-Jeong Oh, Sang-Seol Jung, Jong-Man Won, Seung-Nam Kim, Su-Mi Chung
Cancer Res Treat. 2006;38(1):40-47.   Published online February 28, 2006
DOI: https://doi.org/10.4143/crt.2006.38.1.40
AbstractAbstract PDFPubReaderePub
Purpose

To evaluate the effect of the simulation method on recurrence among the patients who received radiotherapy after breast-conserving surgery (BCS) for early breast carcinoma.

Materials and Methods

Between 1995 and 2000, 70 patients with stage I-II breast carcinoma underwent breast-conserving surgery and adjuvant radiotherapy. Twenty nine patients (41.4%) were simulated with the 2D contour-based method (September 1995 to August 1997) and 41 patients (58.6%) were simulated with the 3D CT-based method (September 1997 to February 2000). To analyze the effect of the simulation method, the patient and treatment characteristics were compared.

Results

The characteristics were similar for the patients between the 2D contour-based simulation group and the 3D CT-based simulation group. During a median follow-up period of 75 months, 4 (13.8%) of 29 patients who were treated with 2D simulation and 1 (2.4%) of 41 patients who were treated with 3D simulation group developed treatment failure. The five-year survival rates were 89.2% and 95.1% between the 2D and 3D simulation groups (p=0.196). The five-year disease free survival (DFS) rates were 86.2% and 97.5% between the 2D and 3D simulation groups (p=0.0636). On univariate analysis, age > 40 (p= 0.0226) and the number of dissected axillary lymph node ≥ 10 (p=0.0435) were independent predictors of improved 5-year DFS.

Conclusions

Although our data showed marginal significance for the DFS between the two groups, it is insufficient, due to the small number of patients in our study, to prove whether 3D CT-based simulation might improve the DFS and reduce the risk of recurrence when compared with 2D contour-based simulation. Further study is needed with a larger group of patients.

  • 11,432 View
  • 46 Download
Close layer
Case Report
The Role of Radiation Therapy for the Extramammary Paget's Disease of the Vulva ; Experience of 3 Cases
Seok-Hyun Son, Jung-Seok Lee, Yeon-Sil Kim, Mi-Ryeong Ryu, Su-Mi Chung, Sung-Eun Namkoong, Gu-Taek Han, Hee-Jeong Lee, Sei-Chul Yoon
Cancer Res Treat. 2005;37(6):365-369.   Published online December 31, 2005
DOI: https://doi.org/10.4143/crt.2005.37.6.365
AbstractAbstract PDFPubReaderePub

We have experienced three cases of extramammary Paget's disease (EMPD) of the vulva that received radiation therapy (RT). Here, we analyze the efficacy of RT and include a literature survey.

Three patients with EMPD of the vulva were treated with curative RT between 1993 and 1998. One of the patients had associated underlying adenocarcinoma of the vulva. The total doses of radiation administered were 54~78 Gy/6~8 weeks. Radiation fields encompassed 2 to 3 cm outer margins free from all visible disease including or not including the inguinal area using a 9 MeV electron or a 6 MV photon beam. Follow-up durations after radiotherapy were 0.6~11 years. Complete response was obtained in all three patients. Marginal failure occurred in one patient, and another patient with underlying adenocarcinoma treated by vulvectomy with bilateral inguinal lymph node dissection followed by external RT showed no relapse. Radiation induced side effects were transient acute confluent wet desquamation in the treated area resulting in mild late atrophic skin changes.

Although surgery is currently considered the preferred primary treatment for EMPD, it has a high relapse rate due to the multifocal nature of the disease. We conclude that RT is of benefit in some selected cases of EMPD.

Citations

Citations to this article as recorded by  
  • Anatomic Subtype Differences in Extramammary Paget Disease
    Nour Kibbi, Joshua L. Owen, Brandon Worley, Jake X. Wang, Vishnu Harikumar, Sumaira Z. Aasi, Sunandana Chandra, Jennifer N. Choi, Yasuhiro Fujisawa, Christos Iavazzo, John Y. S. Kim, Naomi Lawrence, Mario M. Leitao, Allan B. MacLean, Jeffrey S. Ross, Anth
    JAMA Dermatology.2024; 160(4): 417.     CrossRef
  • Vulvar Paget Disease: a series of cases in southern Brazil
    Marcella B. Persiano, Elisa T. Rosin, Giovana A. Cabrera, Fernanda Uratani, Leticia V. Pires, Felipe Luzzatto, Kathleen M. Schmeler, Mila P. Salcedo
    Journal of Global Health Reports.2023;[Epub]     CrossRef
  • The Paget Trial: topical 5% imiquimod cream for noninvasive vulvar Paget disease
    Michelle van der Linden, Colette L. van Hees, Marc van Beurden, Johan Bulten, Eleonora B. van Dorst, Martha D. Esajas, Kim A. Meeuwis, Dorry Boll, Mariëtte I. van Poelgeest, Joanne A. de Hullu
    American Journal of Obstetrics and Gynecology.2022; 227(2): 250.e1.     CrossRef
  • Genomic Alterations as Potential Therapeutic Targets in Extramammary Paget’s Disease of the Vulva
    Marina Stasenko, Gowtham Jayakumaran, Renee Cowan, Vance Broach, Dennis S. Chi, Anthony Rossi, Travis J. Hollman, Ahmet Zehir, Nadeem R. Abu-Rustum, Mario M. Leitao
    JCO Precision Oncology.2020; (4): 1054.     CrossRef
  • Invasive Vulval Paget’s disease treated with primary radiotherapy: A rare case report and literature review
    Avir Sarkar, S.C. Saha, Pooja Sikka, Neha Kumari, Pranab Dey, Bhavana Rai
    Gynecologic Oncology Reports.2020; 34: 100674.     CrossRef
  • Nonsurgical Treatments for Extramammary Paget Disease: A Systematic Review and Meta-Analysis
    Igor Snast, Eran Sharon, Ran Kaftory, Yehonatan Noyman, Meital Oren-Shabtai, Moshe Lapidoth, Emmilia Hodak, Daniel Mimouni, Sigal Mazor, Assi Levi
    Dermatology.2020; 236(6): 493.     CrossRef
  • A Rare Case of Recurrent Paget’s Disease of the Vulva and Gluteal Region Treated with Radiation Therapy
    Mirza Athar Ali, M. Babaiah, Prabhakar Mariappan, Sudha Sinha, KR Muralidhar, Srinivas Ponaganti, Pranav Ashwin Shah, Sujana Priya Vuba, Arun Kumar Reddy Gorla, Deepak Koppaka
    Applied Radiation Oncology.2020; : 44.     CrossRef
  • Efficacy of low‐dose 5‐fluorouracil/cisplatin therapy for invasive extramammary Paget's disease
    Hiroshi Kato, Shoichi Watanabe, Kiyonori Kariya, Motoki NAKAMURA, Akimichi Morita
    The Journal of Dermatology.2018; 45(5): 560.     CrossRef
  • The Role of Radiotherapy in Extramammary Paget Disease
    L. Tagliaferri, C. Castà, G. Macchia, A. Pesce, G. Garganese, B. Gui, G. Perotti, S. Gentileschi, F. Inzani, R. Autorino, S. Cammelli, A.G. Morganti, V. Valentini, M.A. Gambacorta
    International Journal of Gynecological Cancer.2018; 28(4): 829.     CrossRef
  • The Paget Trial: A Multicenter, Observational Cohort Intervention Study for the Clinical Efficacy, Safety, and Immunological Response of Topical 5% Imiquimod Cream for Vulvar Paget Disease
    Michelle van der Linden, Kim Meeuwis, Colette van Hees, Eleonora van Dorst, Johan Bulten, Tjalling Bosse, Joanna IntHout, Dorry Boll, Brigitte Slangen, Manon van Seters, Marc van Beurden, Mariëtte van Poelgeest, Joanne de Hullu
    JMIR Research Protocols.2017; 6(9): e178.     CrossRef
  • Paget disease of the vulva
    M. van der Linden, K.A.P. Meeuwis, J. Bulten, T. Bosse, M.I.E. van Poelgeest, J.A. de Hullu
    Critical Reviews in Oncology/Hematology.2016; 101: 60.     CrossRef
  • Primary extramammary invasive Paget’s vulvar disease: what is the standard, what are the challenges and what is the future for radiotherapy?
    Maria Tolia, Nikolaos Tsoukalas, Chrisostomos Sofoudis, Constantinos Giaginis, Despoina Spyropoulou, Dimitrios Kardamakis, Vasileios Kouloulias, George Kyrgias
    BMC Cancer.2016;[Epub]     CrossRef
  • Extramammary Paget Disease of the Vulva: Minimal Excision with Adjuvant Radiation Treatment for Optimal Aesthetic Results
    Myeong Su Jeon, Gyu Yong Jung, Joon Ho Lee, Kyung Won Kang, Kwang Won No
    Tumori Journal.2016; 102(2_suppl): S84.     CrossRef
  • Paget Disease of the Vulva: Diagnosis by Immunohistochemistry
    Andressa Gonçalves Amorim, Brunelle Batista Fraga Mendes, Rodrigo Neves Ferreira, Antônio Chambô Filho
    Case Reports in Dermatological Medicine.2015; 2015: 1.     CrossRef
  • Radiation therapy for extramammary Paget's disease: treatment outcomes and prognostic factors
    M. Hata, I. Koike, H. Wada, E. Miyagi, T. Kasuya, H. Kaizu, T. Matsui, Y. Mukai, E. Ito, T. Inoue
    Annals of Oncology.2014; 25(1): 291.     CrossRef
  • Radiotherapy in Patients with Extramammary Paget's Disease - Our Own Experience and Review of the Literature
    Tomohiro Itonaga, Hidetsugu Nakayama, Mitsuru Okubo, Ryuji Mikami, Sachica Nogi, Yu Tajima, Shinji Sugahara, Koichi Tokuuye
    Oncology Research and Treatment.2014; 37(1-2): 18.     CrossRef
  • Extramammary Paget's Disease of the Vulva: A Case Report and Review of the Literature
    Nirmala Duhan, Mansi Juneja, Sunita Singh
    Journal of Gynecologic Surgery.2013; 29(6): 297.     CrossRef
  • HDR-plesiotherapy for the treatment of anogenital extramammary Paget's disease
    Soraya Marcos, Angel Montero, Belén Capuz, Javier Martinez-Ollero, Raúl Hernanz, Eva Fernández, Alfredo Polo, Alfredo Ramos
    Reports of Practical Oncology & Radiotherapy.2012; 17(3): 163.     CrossRef
  • Extramammary Paget's disease treated with topical imiquimod 5% cream
    Sue-Ann J. E. Ho, Derrick C. W. Aw
    Dermatologic Therapy.2010; 23(4): 423.     CrossRef
  • 13,507 View
  • 134 Download
  • 19 Crossref
Close layer
Original Article
Clinical Experience of Patients with Ductal Carcinoma In Situ of the Breast Treated with Breast-Conserving Surgery plus Radiotherapy: A Preliminary Report
Ji-Young Jang, Mi-Ryeong Ryu, Sung-Whan Kim, Chul-Seung Kay, Yeon-Sil Kim, Yoon-Kyeong Oh, Hyung-Chul Kwon, Sei-Chul Yoon, Woo-Chan Park, Byung-Joo Song, Se-Jeong Oh, Sang-Seol Jung, Jong-Man Won, Seung-Nam Kim, Su-Mi Chung
Cancer Res Treat. 2005;37(6):344-348.   Published online December 31, 2005
DOI: https://doi.org/10.4143/crt.2005.37.6.344
AbstractAbstract PDFPubReaderePub
Purpose

Breast-conserving therapy (BCT) is a practical alternative to mastectomy for treating ductal carcinoma in situ (DCIS). We reviewed our experience for treating patients with DCIS of the breast to evaluate the outcome after performing breast-conserving surgery plus radiotherapy (BCS-RT).

Materials and Methods

Between January 1983 and December 2002, 25 patients with clinically or mammographically detected DCIS were treated by BCS-RT. One patient was diagnosed with bilateral DCIS. Thirteen cases (50%) had symptomatic lesions at presentation. All 26 cases of 25 patients underwent BCS such as lumpectomy, partial mastectomy or quadrantectomy. All of them received whole breast irradiation to a median dose of 50.4 Gy. Twenty-four cases (92.3%) received a boost to the tumor bed for a median total dose of 59.4 Gy. The median follow up period was 67 months (range: 38 to 149 months).

Results

Two cases (7.7%) experienced ipsilateral breast tumor recurrence (IBTR) after BCS-RT. The histology results at the time of IBTR showed invasive ductal carcinoma (IDC), and the median time to IBTR was 25.5 months. On the univariate analysis, there were no significant factors associated with IBTR in the DCIS patients. The three-year local recurrence free survival rate was 96.0% and the overall survival rate was 96.3%.

Conclusion

After the treatment for DCIS, the IBTR rate in our study was similar to other previous studies. Considering that we included patients who had many symptomatic lesions, close or positive margins and less that complete early data, our result is comparable to the previous studies. We could not find the prognostic significant factors associated with IBTR after BCS-RT. A longer follow up period with more patients would be required to evaluate the role of any predictive factors and to confirm these short-term results.

  • 8,504 View
  • 56 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP